1.	Phase I/II Study Evaluating the Safety and Biological Activity of Recombinant Vaccinia Prostate-Specific Antigen (Vaccinia-PSA) Vaccine in Patients with Serological Recurrence of Prostate Cancer Following Radical Prostatectomy (Summary Last Modified 09/2000) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: not specified Sponsor: NCI Protocol IDs: CCUM-9618, NCI-T97-0007, T97-0007
2.	Phase II Randomized Study of Radiotherapy With or Without Vaccination Comprising Recombinant Vaccinia-PSA and rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine in Patients With Localized Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-00-C-0154, NCI-NMOB-B00-021, NCI-894, 894, NCT00020228
3.	Phase II Randomized Study of Vaccine Containing Recombinant Vaccinia-Prostate-Specific Antigen (PSA) Admixed With rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine, Sargramostim (GM-CSF), and Interleukin-2 Versus Nilutamide Alone in Patients With Hormone-Refractory Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-00-C-0137, MB-NAVY-99-04, NCI-T99-0097, T99-0097, NCT00020254
4.	Phase II Pilot Randomized Study of Fowlpox (Pox Vector)-Prostate-Specific Antigen Vaccine With or Without Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-02-C-0218, NCI-5319, 5319, NCT00045227
5.	PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000067036, E-7897, NCT00003871
6.	Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000065275, DFCI-96079, NCI-T95-0086H, T95-0086, NCT00004029